Literature DB >> 20700898

Targeted therapies: Activated PI3K/AKT confers resistance to trastuzumab but not lapatinib.

Lisa Hutchinson.   

Abstract

Entities:  

Year:  2010        PMID： 20700898     DOI： 10.1038/nrclinonc.2010.113

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.

Authors:  Neil A O'Brien; Brigid C Browne; Lucy Chow; Yuhua Wang; Charles Ginther; Jane Arboleda; Michael J Duffy; John Crown; Norma O'Donovan; Dennis J Slamon
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261
  1 in total
  4 in total

Review 1.  The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.

Authors:  Elisabeth J Diver; Rosemary Foster; Bo R Rueda; Whitfield B Growdon
Journal:  Oncologist       Date:  2015-06-22

2.  Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.

Authors:  Andrew Sewell; Brandee Brown; Asel Biktasova; Gordon B Mills; Yiling Lu; Darren R Tyson; Natalia Issaeva; Wendell G Yarbrough
Journal:  Clin Cancer Res       Date:  2014-03-05       Impact factor: 12.531

3.  Novel agents that downregulate EGFR, HER2, and HER3 in parallel.

Authors:  Renan Barroso Ferreira; Mary Elizabeth Law; Stephan Christopher Jahn; Bradley John Davis; Coy Don Heldermon; Mary Reinhard; Ronald Keith Castellano; Brian Keith Law
Journal:  Oncotarget       Date:  2015-04-30

4.  The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.

Authors:  Hui Lyu; Xiao He Yang; Susan M Edgerton; Ann D Thor; Xiaoying Wu; Zhimin He; Bolin Liu
Journal:  Oncotarget       Date:  2016-01-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.